DEF 14A: Atara Biotherapeutics Seeks Stockholder Approval for Reverse Stock Split and Equity Incentive Plan

Atara Biotherapeutics is asking stockholders to approve a reverse stock split, elect directors, approve executive compensation, ratify the selection of its auditor, and approve its equity incentive plan at the upcoming annual meeting.

Summary

• Atara Biotherapeutics is holding its Annual Meeting of Stockholders on June 10, 2024, virtually.
• Stockholders will vote on several proposals, including the election of two directors, an advisory vote on executive compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm.
• The company is also seeking approval for its 2024 Equity Incentive Plan, an automatic annual increase to the plan, and an increase in the number of shares available under the 2014 Employee Stock Purchase Plan.
• A key proposal is an amendment to the company's certificate of incorporation to effect a reverse stock split at a ratio ranging from 1-for-4 to 1-for-30.
• The board has the authority to abandon the reverse stock split.
• The company is also seeking approval to adjourn the Annual Meeting if necessary to solicit additional proxies for the reverse stock split proposal.
• The board recommends voting in favor of all proposals.
• The company is focused on applying EBV T-cell biology and novel chimeric antigen receptor (CAR) technologies to enter new frontiers of cell therapy for patients with cancer and autoimmune diseases.
• The company is the first company in the world to receive regulatory approval for an allogeneic T-cell immunotherapy with the approval of Ebvallo by the European Commission (EC).

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. While there are achievements and future plans, the need for a reverse stock split and the failure of a key trial temper the overall outlook.

Positives

• The company is the first company in the world to receive regulatory approval for an allogeneic T-cell immunotherapy with the approval of Ebvallo by the European Commission (EC).
• The company has aligned with the FDA on analytical comparability between manufacturing process versions, supporting its ability to pool the pivotal clinical trial data from different process versions in the biologics license application (BLA) submission.
• The company has consummated expansion of global partnership with Pierre Fabre Medicament (Pierre Fabre) to include the United States and all remaining markets, with the Company to receive up to $640M in additional payments, significant double-digit tiered royalties and funding of tab-cel global development costs.
• The company has submitted Investigational New Drug (IND) application for ATA3219 for the treatment of non-Hodgkins lymphoma in June 2023 and obtained safe to proceed notice from FDA in July 2023.

Negatives

• The company's stock options are significantly underwater.
• The company's stock price has been below the minimum bid price for continued inclusion on the Nasdaq Global Select Market.
• The company's EMBOLD primary analysis data were not sufficient to enable a successful partnering transaction in the first half of 2024.

Risks

• There is no guarantee that the reverse stock split will increase the stock price or enable the company to maintain its Nasdaq listing.
• The reverse stock split could negatively impact the marketability and liquidity of the company's stock.
• The company's systems and networks remain potentially vulnerable to known or unknown cybersecurity attacks and other threats, any of which could have a material adverse effect on our consolidated results of operations, financial condition and cash flows.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement and continue developing novel investigational treatments for patients with cancer and autoimmune diseases.

Management Comments

• The Board believes that diversity of viewpoints, background, experience, and other characteristics, such as race, gender, ethnicity, sexual orientation, culture and nationality, are an important part of its makeup, and the Nominating and Corporate Governance Committee and the Board actively seek these characteristics in identifying director candidates.
• We are committed to building a safe, environmentally sustainable and ethical business that provides long-term value for all Atara stakeholders.

Industry Context

The document highlights Atara's position in the competitive biotechnology industry, particularly in cell and gene therapy, and emphasizes the need to attract and retain talent in this landscape.

Comparison to Industry Standards

• The document compares Atara's executive compensation practices to a peer group of 20 publicly-traded, U.S-based biotechnology/pharmaceutical companies.
• The peer group includes companies such as Agenus Inc., Alector Inc., Allogene Therapeutics Inc., and Fate Therapeutics, Inc.
• The document mentions that many companies that Atara competes with for talent offer a similar employee stock purchase program.

Stakeholder Impact

• The reverse stock split could impact shareholders by potentially increasing the stock price and improving marketability, but also carries the risk of further decline.
• The equity incentive plan aims to attract and retain employees, which could benefit the company's long-term success.
• The company's focus on developing new therapies could benefit patients with cancer and autoimmune diseases.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on June 10, 2024.
• The board will decide whether to implement the reverse stock split based on market conditions and other factors.
• The company will continue to develop its pipeline and seek regulatory approvals for its therapies.

Key Dates

Keywords

reverse stock split, equity incentive plan, executive compensation, annual meeting, directors, stockholders, Atara Biotherapeutics, proxy statement